Q-omics provides the consensus-scored DCUN1D5 profile across patient tissues and cancer cell-line models. DCUN1D5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DCUN1D5 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, DCUN1D5 RNA expression shows 18,869 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where DCUN1D5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCUN1D5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCUN1D5 survival associations across molecular data types. DCUN1D5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCUN1D5 RNA expression–survival associations across cancer types. High DCUN1D5 expression shows unfavorable associations in ACC, LIHC, UVM, KIRP, KICH and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DCUN1D5 RNA expression.
This table summarizes DCUN1D5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DCUN1D5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCUN1D5 shows higher tumor expression in HNSC, COAD, KIRC, BLCA, LIHC and LUAD. The HNSC box plot shows higher DCUN1D5 RNA expression in tumor versus normal tissue (log2 FC = +1.353, t-test p < 0.001).
This table shows molecular features associated with DCUN1D5 in patient tissues and cancer cell lines. In patient samples, DCUN1D5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DCUN1D5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
